Business Context and Reporting Period
This Form 8-K, filed on March 17, 2023, reports the completion of a reverse merger between Graybug Vision, Inc. and CalciMedica, Inc. on March 20, 2023. Graybug Vision, Inc. changed its name to CalciMedica, Inc. (the "Company") and adopted the ticker symbol "CALC." The transaction was structured as a reverse recapitalization, with CalciMedica deemed the accounting acquirer. The Company is a clinical-stage biopharmaceutical firm focused on developing therapies for life-threatening inflammatory diseases, specifically targeting calcium-release activated calcium (CRAC) channels. Its lead product candidate, Auxora, is in development for acute pancreatitis.
Key Financial Metrics and Capital Structure
As this is a current report regarding a merger and not a periodic financial statement, specific revenue, profit, or cash flow metrics for the combined entity are not provided in this filing. However, the following capitalization and financing details are disclosed:
- Private Placement: Immediately prior to the merger, CalciMedica raised approximately $10.3 million through the sale of approximately 20.7 million shares of common stock.
- Merger Consideration: CalciMedica shareholders received 3,946,538 shares of Graybug common stock (post-split) based on an exchange ratio of 0.0288 shares of Graybug stock for each CalciMedica share.
- Post-Merger Ownership: Immediately following the merger, there were 5,517,754 shares of common stock issued and outstanding. Prior CalciMedica equityholders own approximately 72% of the Company, while prior Graybug equityholders own approximately 28% (on a fully diluted basis).
- Debt Conversion: Approximately $8.5 million in convertible promissory notes issued between April and November 2022 were converted into common stock immediately prior to the merger.
- Stock Split: Graybug executed a 14:1 reverse stock split effective March 20, 2023.
Material Changes and Corporate Actions
- Change of Control: The merger resulted in a change of control, with CalciMedica's board and management assuming majority control of the combined entity.
- Executive Departures: Graybug's former CEO Frederic Guerard and CFO Robert S. Breuil were terminated effective at the merger closing. Their outstanding stock options and RSUs were accelerated in full under the Change in Control Severance Policy.
- Management Appointments: A. Rachel Leheny, Ph.D., was appointed CEO and Class II Director. Daniel Geffken, MBA, was appointed Interim CFO. The new board consists of seven members, five of whom are designees of CalciMedica.
- Delisting Notice: On March 21, 2023, the Company received notice from Nasdaq that it failed to meet initial listing requirements (specifically regarding stockholders' equity and market value of publicly held shares). Trading on Nasdaq is scheduled to be suspended on March 30, 2023.
Guidance, Outlook, and Risks
The Company intends to appeal Nasdaq's delisting determination and plans to apply for trading on the OTCQB tier of the over-the-counter market if the appeal is unsuccessful or if trading is suspended. The Company expects to file a Form S-3 registration statement to register the resale of shares issued to CalciMedica stockholders and will file an amendment to this 8-K to include required financial statements within 71 days.
Key Risks and Contingencies:
- Trading Suspension: The immediate risk of trading suspension on Nasdaq and potential trading on lower-tier OTC markets, which may impact liquidity and stock price.
- Listing Compliance: Uncertainty regarding the ability to satisfy Nasdaq listing requirements in time to avoid suspension.
- Regulatory Approval: The Company's future success depends on obtaining regulatory approval for its lead candidate, Auxora.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the merger benefits, listing status, and product development, which are subject to significant risks and uncertainties.
Investor Verification Checklist
- Verify the status of the Company's appeal to Nasdaq and the outcome of the hearing scheduled for March 28, 2023.
- Confirm the Company's trading venue following the March 30, 2023 suspension (OTCQB vs. Pink Current Information).
- Review the upcoming Form 8-K/A amendment (due within 71 days) for the required financial statements of the acquired business and pro forma financial information.
- Monitor the filing of the Form S-3 registration statement for the resale of shares issued to CalciMedica stockholders.
- Assess the impact of the 72% ownership concentration by former CalciMedica equityholders on corporate governance and future financing.